You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Johnson and Johnson
Colorcon
Baxter
Mallinckrodt

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MIDODRINE HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for MIDODRINE HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004268 Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension Completed Roberts Pharmaceutical Phase 2 2001-04-01 OBJECTIVES: I. Study further the safety and efficacy of the alpha-receptor agonist midodrine in patients with neurogenic orthostatic hypotension. II. Assess the quality of life in these patients with this treatment regimen.
NCT00004268 Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension Completed National Center for Research Resources (NCRR) Phase 2 2001-04-01 OBJECTIVES: I. Study further the safety and efficacy of the alpha-receptor agonist midodrine in patients with neurogenic orthostatic hypotension. II. Assess the quality of life in these patients with this treatment regimen.
NCT00004479 Randomized Study of Midodrine, an Alpha Adrenergic Agonist, in Patients With Neurally Mediated Syncope Completed Icahn School of Medicine at Mount Sinai N/A 1999-03-01 OBJECTIVES: Determine the efficacy of midodrine, a selective alpha 1 adrenergic agonist, in preventing neurally mediated syncope.
NCT00046163 A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension Terminated Shire Phase 4 2002-09-01 We are seeking male and female patients to voluntarily take part in a clinical research study. Patients must be aged 18 or older and diagnosed with symptomatic orthostatic hypotension (low blood pressure while in the upright position) due to Parkinson's disease, multiple system atrophy, pure autonomic failure or autonomic neuropathies (i.e. neurogenic orthostatic hypotension). Symptoms of low blood pressure include dizziness, lightheadedness, changes in vision and generalized weakness upon standing. The main effect of the drug being studied is to increase blood pressure in the upright position so symptoms will decrease. The purpose of this clinical study is to further assess the clinical effect of high dose midodrine hydrochloride (ProAmatine®), an approved treatment for orthostatic hypotension. During the course of the study, participants will receive either ProAmatine® or a placebo. Assessments will be made using questionnaires that measure symptom and activity levels. Blood pressure in the lying down, sitting and standing positions will be measured. Patients will also complete standing time assessments. They will be asked to remain standing without moving until they feel sufficiently lightheaded, or dizzy, or feel faint so that they would feel more comfortable sitting down.
NCT00046475 A Study for Patients With Neurogenic Orthostatic Hypotension Completed Shire Phase 4 2002-01-01 We are seeking male and female patients to voluntarily take part in a clinical research study. Patients must be aged 18 or older and diagnosed with symptomatic orthostatic hypotension (low blood pressure while in the upright position) due to Parkinson's disease, multiple system atrophy, pure autonomic failure or autonomic neuropathies (i.e. neurogenic orthostatic hypotension). Symptoms of low blood pressure include dizziness, lightheadedness, changes in vision and generalized weakness upon standing. The main effect of the drug being studied is to increase blood pressure in the upright position so symptoms will decrease. The purpose of this clinical study is to further assess the clinical benefit of midodrine hydrochloride (ProAmatine®), an approved treatment for orthostatic hypotension. During the course of the study, participants will receive either ProAmatine® or a placebo. Assessments will be made using questionnaires that measure symptom and activity levels. Blood pressure in the lying down and standing positions will be measured at each visit.
NCT00108355 Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis Completed VA Office of Research and Development Phase 4 2003-12-01 This clinical trial compares a combination of two drugs that constrict blood vessels (Octreotide LAR and Midodrine) to albumin after large volume paracentesis. Subjects have cirrhosis and ascites.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for MIDODRINE HYDROCHLORIDE

Condition Name

Condition Name for MIDODRINE HYDROCHLORIDE
Intervention Trials
Orthostatic Hypotension 10
Cirrhosis 7
Hepatorenal Syndrome 5
Neurogenic Orthostatic Hypotension 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for MIDODRINE HYDROCHLORIDE
Intervention Trials
Hypotension 31
Hypotension, Orthostatic 24
Syndrome 10
Hepatorenal Syndrome 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for MIDODRINE HYDROCHLORIDE

Trials by Country

Trials by Country for MIDODRINE HYDROCHLORIDE
Location Trials
United States 169
Canada 23
India 8
Australia 6
Egypt 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for MIDODRINE HYDROCHLORIDE
Location Trials
New York 21
Tennessee 10
Texas 9
Ohio 8
Florida 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for MIDODRINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for MIDODRINE HYDROCHLORIDE
Clinical Trial Phase Trials
Phase 4 20
Phase 3 12
Phase 2/Phase 3 4
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for MIDODRINE HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 29
Recruiting 22
Not yet recruiting 17
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for MIDODRINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for MIDODRINE HYDROCHLORIDE
Sponsor Trials
James J. Peters Veterans Affairs Medical Center 7
Chelsea Therapeutics 6
Institute of Liver and Biliary Sciences, India 6
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for MIDODRINE HYDROCHLORIDE
Sponsor Trials
Other 67
Industry 21
U.S. Fed 11
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Medtronic
Harvard Business School
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.